Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics (NQ: FOLD )

10.35 +0.01 (+0.10%)
Streaming Delayed Price Updated: 3:08 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,156,263
Open 10.40
Bid (Size) 10.34 (17)
Ask (Size) 10.35 (4)
Prev. Close 10.34
Today's Range 10.26 - 10.57
52wk Range 9.700 - 14.57
Shares Outstanding 266,555,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
From Amicus Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-27.32%
-27.32%
1 Month
-10.78%
-10.78%
3 Month
-18.50%
-18.50%
6 Month
-8.49%
-8.49%
1 Year
-15.02%
-15.02%

More News

Read More
Amicus Therapeutics Stock Sees RS Rating Improve To 74
Via Investor's Business Daily
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
The Analyst Landscape: 4 Takes On Amicus Therapeutics
Via Benzinga
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Stock Sees Improved Relative Strength Rating
Via Investor's Business Daily
Amicus Therapeutics Receives the 2024 New Treatment Award for Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) at the 20th Annual WORLDSymposium™
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Presentations and Posters at the 20th Annual WORLDSymposium™ 2024
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Time to buy these 3 healthcare companies that raised revenue guidance?
Via MarketBeat
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
From Amicus Therapeutics, Inc.
Via GlobeNewswire
7 Stocks Most Likely to Follow in WeWork’s Woeful Footsteps
Via InvestorPlace
Topics Bankruptcy
Exposures Financial Legal
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics to Announce Third Quarter 2023 Financial Results on November 8, 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Announces Presentation and Posters at World Muscle Society 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics and Blackstone Enter into $430 Million Strategic Financing Collaboration
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Nike, OPKO Health And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Via Benzinga
Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe Disease
Via Benzinga
Exposures Product Safety
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Amicus Therapeutics Stock Reaches 80+ Relative Strength Benchmark
Via Investor's Business Daily
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2023
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.